Icahn Enterprises Holdings

Icahn Enterprises is a diversified holding company that operates across several primary business segments, including a dedicated pharmaceutical division. The company's healthcare operations are primarily conducted through its subsidiary, Vivus, which focuses on the development and commercialization of therapies for obesity, urology, and digestive health. Its commercial portfolio includes Qsymia for chronic weight management, STENDRA for erectile dysfunction, and PANCREAZE for exocrine pancreatic insufficiency. Structured as a master limited partnership controlled by activist investor Carl Icahn, the firm utilizes its investment expertise to manage and expand its specialty pharmaceutical assets. The company also maintains a clinical pipeline exploring new indications for existing assets, such as pulmonary arterial hypertension.